```
AN - 2002-106203 [14]
```

AP - AU20010075637 20010514; [Based on WO0190376]; WO2001CN00769 20010514; CN20000115710 20000516

CPY - SHAN-N

- SHAN-N

DC - B04 D16

DS - BE CY EA FR GR IE IT MC NL OA SZ

FS - CPI

IC - A61K38/52; C07K14/745; C07K16/40; C12N9/90; C12N15/57; C12N15/61; C12N15/63; C12Q1/533; C12Q1/68

IN - MAO Y: XIE Y

MC - B04-C01G B04-E03E B04-E05 B04-E06 B04-E08 B04-F0100E B04-G03 B04-L0700E B11-C08 B11-C08E3 B11-C08E5 B12-K04A B12-K04F B14-A02B1 B14-C03 B14-F02 B14-F08 B14-G03 B14-H01 B14-S03 D05-C03F D05-H09 D05-H11 D05-H12A D05-H12D1 D05-H12D2 D05-H12E D05-H14 D05-H17A3

M1 - [01] M423 M710 M905 Q233; RA00C8-N

- [02] M423 M710 M905 N135 N136 Q233; RA00GT-N
- [03] M423 M710 M720 M750 M781 M905 N102 N135 N136 N161 P210 P420 P433 P434 P520 P633 P815 P831 Q233 Q505; RA2UAN-T RA2UAN-A RA2UAN-D RA2UAN-N RA2UAN-P
- [04] M423 M710 M720 M750 M781 M905 N102 N135 N136 N161 P210 P420 P433 P434 P520 P633 P815 P831 Q233 Q505; RA00H3-T RA00H3-A RA00H3-D RA00H3-N RA00H3-P
- [05] M423 M710 M720 M750 M781 M905 N102 N135 N136 N161 P210 P420 P433 P434 P520 P633 P815 P831 Q233 Q505; RA00H1-T RA00H1-A RA00H1-D RA00H1-N RA00H1-P
- [06] M423 M710 M750 M781 M905 N102 N134 N135 N136 N161 P210 P420 P433 P434 P520 P633 P815 P831 Q233 Q505; RA012P-T RA012P-A RA012P-D RA012P-N
- [07] M423 M710 M750 M781 M905 N102 N134 N135 N136 N161 P210 P420 P433 P434 P520 P633 P815 P831 Q233 Q505; RA00NS-T RA00NS-A RA00NS-D RA00NS-N
- M6 [08] M905 P210 P420 P433 P434 P520 P633 P815 P831 Q233 Q505 R515 R521 R624 R627 R632 R633 R639
- PA (SHAN-N) SHANGHAI BIOWINDOW GENE DEV INC
  - (SHAN-N) SHANGHAI BODE GENE DEV CO LTD
- PN AU200175637 A 20011203 DW200221 C12N15/57 000pp
  - WO0190376 A1 20011129 DW200214 C12N15/57 Chn 036pp
  - CN1323902 A 20011128 DW200219 C12N15/61 000pp
- PR CN20000115710 20000516
- XA C2002-032600
- XIC A61K-038/52; C07K-014/745; C07K-016/40; C12N-009/90; C12N-015/57; C12N-015/61; C12N-015/63; C12Q-001/533; C12Q-001/68
- AB WO200190376 NOVELTY An isolated polypeptide (I) of human triose phosphate isomerase 11 containing a 98 amino acid sequence (S1), given in the specification, or its fragment, analog or derivative, is new.
  - DETAILED DESCRIPTION INDEPENDENT CLAIMS are also included for the following:
  - (1) an isolated polynucleotide (II):
  - (a) encoding (S1), or its fragment, analog or derivative;
  - (b) complementary to (a); or
  - (c) not less than 70 % homologous to (a) or (b);
  - (2) a recombinant vector (III) containing an exogenous polynucleotide constructed from (II) and a plasmid, virus vector-expressing vector;
  - (3) a genetically-modified host cell (IV) comprising (II) or (III);
  - (4) producing (I) by culturing (IV) before isolating the product:
  - (5) an antibody that specifically binds (I);
  - (6) mimics or regulators of (I) activity or expression, preferably compounds that can mimic, promote, antagonize or inhibit human triose

phosphate isomerase 11;

- (7) using the compounds of (6) for regulating (I) in vivo or in vitro;
- (8) detecting diseases relating to the novel polypeptide or disease susceptibility, by measuring the expression dose of (I), determining (I) activity, or detecting (I) expression dose caused by the polynucleotide that has abnormal activity due to a (II) mutation;

 (9) using (I) for screening mimics, agonists, antagonists or inhibitors, or for use in peptide fingerprinting identification;

- (10) using (II) as a primer for nucleic acid amplification reaction or as a probe for hybridization reaction, or in producing gene chips or microarrays; and
- (11) drug compositions for diseases relating to the (I) containing
  (I), (II), or mimics, agonists, antagonists, or inhibitors and their preparation in safe amounts with pharmaceutically-acceptable carrier, which can be used in diagnostics as well.
- ACTIVITY Cytostatic; hemostatic; virucide; immunomodulatory; antiinflammatory; anti-HIV. No biological data is given.
- MECHANISM OF ACTION Gene therapy.
- USE (I) and nucleic acid (II) are used in diagnosis and treatment of malignant tumor, hemopathy, human immunodeficiency virus (HIV) infection, immunological diseases and various inflammations (claimed).
   (Dwg.0/0)
- CN RÃ00C8-N RA00GT-N RA2UAN-T RA2UAN-A RA2UAN-D RA2UAN-N RA2UAN-P RA00H3-T RA00H3-A RA00H3-D RA00H3-N RA00H3-P RA00H1-T RA00H1-A RA00H1-D RA00H1-N RA00H1-P RA012P-T RA012P-A RA012P-D RA012P-N RA00NS-T RA00NS-A RA00NS-D RA00NS-N
- DN AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
- IW NEW HUMAN TRIOSE PHOSPHATE ISOMERASE POLYPEPTIDE DIAGNOSE TREAT MALIGNANT HUMAN IMMUNODEFICIENCY VIRUS INFECT IMMUNOLOGICAL DISEASE INFLAMMATION
- IKW NEW HUMAN TRIOSE PHOSPHATE ISOMERASE POLYPEPTIDE DIAGNOSE TREAT MALIGNANT HUMAN IMMUNODEFICIENCY VIRUS INFECT IMMUNOLOGICAL DISEASE INFLAMMATION

INW - MAO Y; XIE Y

NC - 095

OPD - 2000-05-16

ORD - 2001-11-28

- PAW (SHAN-N) SHANGHAI BIOWINDOW GENE DEV INC
  - (SHAN-N) SHANGHAI BODE GENE DEV CO LTD
- TI New human triose phosphate isomerase 11 polypeptide for diagnosing and treating malignant tumors, hemopathy, human immunodeficiency virus infection, immunological diseases and inflammation